Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Glutamate receptor ionotropic, kainate 5 (GluK5) is a subunit of the kainate-type ionotropic glutamate receptors, which are cation-permeable ligand-gated ion channels activated by the neurotransmitter L-glutamate and kainic acid. It does not form functional channels on its own but instead assembles with "low-affinity" subunits (e.g., GluK1-3) to create heteromeric functional receptors. These receptors play a crucial role in regulating synaptic transmission, neuronal excitability, and network oscillations in the central nervous system. GluK5-containing receptors have been implicated in numerous CNS pathologies, including epilepsy, neurodegeneration, and psychiatric disorders, making them targets of significant scientific and therapeutic interest.
Agonists (like glutamate and kainic acid) bind and activate the ion channel, leading to cation influx and neuronal depolarization. Antagonists (such as select barbiturates or specific research compounds) block channel activation, inhibiting synaptic transmission.
5 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Glutamate receptor ionotropic, kainate 5 (GluK5).